Top Industry Leaders in the Bile Duct Cancer Market
Iterative Scopes receives FDA Breakthrough Device designation for its CholangioScope™: August 2023, Iterative Scopes received FDA recognition for its CholangioScope™, a miniaturized, steerable endoscope designed for improved bile duct visualization and potentially enhancing early cancer detection.
Blueprint Medicines secures FDA approval for NTRK inhibitor Rozlytrek (entrectinib) for cholangiocarcinoma: July 2023, Blueprint Medicines achieved a significant milestone with FDA approval of Rozlytrek for patients with NTRK gene fusion-positive cholangiocarcinoma, offering a targeted treatment option.
Roche presents positive Phase 2 trial results for Tecentriq (atezolizumab) combination therapy for advanced biliary tract cancer: June 2023, Roche announced promising results from a Phase 2 trial evaluating Tecentriq combined with gemcitabine and cisplatin for the treatment of advanced bile duct cancer.
List of Bile Duct Cancer Key Companies in the Market
- Pfizer Inc. in the U.S.
- Hoffmann-La Roche Ltd in Europe
- Bristol-Myers Squibb Company in the U.S.
- Teva Pharmaceutical Industries Ltd. In the Middle East
- Eli Lilly and Company. In the U.S.
- Sanofi in Europe
- Fresenius Kabi AG in Europe
- Mylan N.V. in the U.S.